

# Interleukin-17 Inhibitors Therapeutic Cheat Sheet

COMPILED BY: ANGELO LANDRISCINA, MD • REVIEWED BY: ADAM FRIEDMAN, MD

## DRUGS

- › Secukinumab (Cosentyx)
- › Ixekizumab (Taltz)
- › Brodalumab (Siliq)

## MECHANISM

- › Secukinumab – IgG1 monoclonal antibody binding IL-17A
- › Ixekizumab – IgG4 monoclonal antibody binding IL-17A
- › Brodalumab – IgG2 monoclonal antibody binding IL-17 receptor A, blocking activity of IL-17A,F,A/F and E.

## FDA APPROVED FOR

- › Secukinumab – Adult plaque psoriasis (with sebopsoriasis data included on label), psoriatic arthritis and ankylosing spondylitis
- › Ixekizumab – Adult plaque psoriasis (with genital psoriasis data included on label), psoriatic arthritis and ankylosing spondylitis
- › Brodalumab – Adult plaque psoriasis

## OFF-LABEL USES

Hidradenitis suppurativa, Bechet's disease, lichen planus, pustular psoriasis, impetigo herpetiformis, rheumatoid arthritis, pityriasis rubra pilaris

## DOSING

- › Secukinumab – 300 mg SQ wk 0,1,2,3,4 then every 4 weeks
- › Ixekizumab – 160 mg SQ wk 0, 80 mg wk 2,4,6,8,10,12 then every 4 weeks
- › Brodalumab – 210 mg SQ wk 0,1,2 then every 2 weeks

## SIDE EFFECTS

### As a class:

- › rare reports of drug-neutralizing antibodies, increased risk of infection (particularly mucocutaneous candidiasis), development of new or flaring of IBD, neutropenia, hepatotoxicity, injection site reaction

### Specific:

- › Secukinumab – elevation of LFTs
- › Ixekizumab – injection site pain
- › Brodalumab – reports of suicidal ideation and completed suicides in clinical trials

## PREGNANCY AND LACTATION

Data is incomplete with conflicting animal data (no harm to developing fetus though increased fetal death with high doses of ixekizumab). No data about excretion in breast milk.

## MONITORING

**Baseline:** Thorough history and physical with special attention to infection history, history of IBD, psychiatric history including thoughts of suicide  
**Labs:** CBC, CMP, TB test such as Quantiferon Gold, HBV and HCV antibody studies, HIV

**Follow Up:** Visits every 3-6 months depending on patient progress. Each visit, special attention to history of infection, new GI symptoms, psychiatric symptoms if on brodalumab. Patients should have regular skin cancer screening and yearly TB test.